Carlsmed, Inc. (CARL) Stock Price & Analysis

Carlsmed, Inc. (CARL) is trading at USD 17.44, down 1.72% today, as of November 18, 2026 at 20:53 UTC (US market open; quotes may be delayed), according to Nexqual market data.

CARL last closed at USD 17.74; today's session has ranged USD 17.32–18.26 on volume of 97,166 shares. Market capitalization is $477.79M, with a 52-week range of USD 8.5–19.15 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CARL.md

Key facts (CARL)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CARL)

USDFY2024FY2025TTM
Revenue$27.2M$50.5M$71.8M
Gross profit$20.0M$38.0M—
Operating income-$24.1M-$30.6M-$42.3M
Net income-$24.3M-$29.6M-$40.1M
EPS (diluted)-$6.11-$2.12—
Free cash flow-$25.6M-$29.6M-$34.9M
Gross margin73.8%75.3%—
Operating margin-88.8%-60.5%-59.0%
Net margin-89.3%-58.7%-55.8%
Revenue growth—+85.9%—
Cash + short-term investments$40.1M$110M—
Total debt$15.4M$15.3M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (CARL)

P/S 6.8x · EV/Sales 6.2x · P/B 6.4x · FCF yield -7.18% · Earnings yield -8.24% · Net cash $44.5M · EV $442M

Insider sales (SEC Form 4, open-market, last ~7 months) (CARL)

4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-11-03Bertolini JeffreyChief Operating Officer747$11K3.2%Yes (adopted March 12, 2026)Too little history (no open-market trades in 2023–2025)
2026-10-30Bertolini JeffreyChief Operating Officer243$4K1.1%Yes (adopted March 12, 2026)Too little history (no open-market trades in 2023–2025)
2026-10-05Bertolini JeffreyChief Operating Officer747$11K3.2%Yes (adopted March 12, 2026)Too little history (no open-market trades in 2023–2025)
2026-09-30Bertolini JeffreyChief Operating Officer243$3K1.1%Yes (adopted March 12, 2026)Too little history (no open-market trades in 2023–2025)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CARL)

Consensus Buy (mean 1.60 on a 1–5 scale), 5 analysts; mean target USD 22 (low 18, high 26).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-11Truist SecuritiesTarget raisedBuy$20 → $23
2026-11-11NeedhamTarget raisedBuy$17 → $22
2026-11-11BTIGTarget raisedBuy$24 → $26
2026-10-12BTIGTarget raisedBuy$23 → $24
2026-09-28BTIGReiteratedBuy$23
2026-08-06Truist SecuritiesTarget raisedBuy$18 → $20

Total return (dividends reinvested) (CARL)

1Y (from 2025-11-18)5Y (from 2025-07-21)
Total return+44.8%+22.3%
S&P 500 (SPY)+11.8%+66.5%
Per year+44.9%+16.4%
Volatility (annualized)74.6%65.4%
Max drawdown-48.0% (Dec 2025→Apr 2026)-45.1% (Nov 2025→Apr 2026)

Dividends (CARL)

CARL paid no cash dividend in the last five years.

Short interest (CARL)

1,241,498 shares sold short, 12.04% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,053,927 shares (+17.8%). Days to cover: 15.1 (short shares ÷ average daily volume).

CARL earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
—Quarter ended Sep 30, 2026−$0.11−$0.38Beat +71.1%—
—Quarter ended Jun 30, 2026−$0.39−$0.39In line—
—Quarter ended Mar 31, 2026−$0.26−$0.39Beat +33.3%—
—Quarter ended Dec 31, 2025−$0.29−$0.43Beat +32.6%—

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

CARL recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 10, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 10, 20268-KQuarterly results
Sep 30, 20268-KDirector or executive officer change, or pay arrangement; Regulation FD disclosure
“Departure of Chief Financial Officer On September 28, 2026, Carlsmed, Inc. (the "Company") announced that Leo Greenstein has departed his role as the Company's Chief Financial Officer, effective September 25, 2026 (the "Separation Date"). The Company appreciates Mr. Greenstein's contributions and wishes him well in his future endeavors. Mr. Greenstein's departure is not a result of any disagreement with the Company's independent auditors or any member of management on any matter of accounting principles or…”
Sep 8, 20268-KDirector or executive officer change, or pay arrangement; Regulation FD disclosure
“On September 4, 2026, the Board of Directors of Carlsmed, Inc. (the "Company") appointed Jeffrey Bertolini as Chief Operating Officer of the Company, effective September 8, 2026. Mr. Bertolini, age 60, has served as the Company's Senior Vice President, Operational Excellence since March 2025. Previously, Mr. Bertolini was Vice President of Advanced Manufacturing Technologies of the Company from September 2024 to March 2025. Before joining the Company, Mr. Bertolini was Senior Vice President, Operations &…”
Aug 5, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 5, 20268-KQuarterly results

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

CARL suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
CompetitorJohnson & Johnson (JNJ)“Our products currently compete with stock implants manufactured or developed by other companies, including Medtronic PLC, Johnson & Johnson, and Globus Medical Inc. Some of these competitors are large, well-capitalized companies with greater market share and resources than we have.”

Quoted from the company's 10-K filed Feb 25, 2026.

CARL customer concentration

In the quarter ended Mar 31, 2025, a single direct customer accounted for 10% of CARL's revenue. The company does not name this customer in the filing. Source: the company's 10-Q filed May 5, 2026.

CARL company outlook (results filed Nov 10, 2026)

Quoted word-for-word from the SEC 8-K results press release.

CARL analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Sep 2026)$-0.39$-0.40+$0.01$19.2M2
Next quarter (ends Dec 2026)$-0.35$-0.30−$0.04$24.3M1
Current fiscal year (ends Dec 2026)$-1.51$-1.41−$0.10$79.3M1
Next fiscal year (ends Dec 2027)$-1.56$-1.38−$0.18$111.9M1

Key Statistics (as of November 18, 2026 at 20:53 UTC)

PriceUSD 17.44
Change▼ 1.72% (down)
Previous CloseUSD 17.74
OpenUSD 17.77
Day RangeUSD 17.32 – 18.26
52-Week RangeUSD 8.5 – 19.15
Volume97,166 shares
Market Cap$477.79M
ExchangeNMS

Technical Analysis (CARL)

Nexqual's technical model rates CARL "STRONG BUY" based on 5 bullish and 0 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.

Overall SignalSTRONG BUY
RSI (14)58.24 (neutral)
vs SMA50Above (USD 15.1)
MACD0.75 (positive)

Analyst Ratings (CARL)

Wall Street analysts rate CARL "Buy" based on 5 analysts, with a mean price target of USD 22 (range USD 18–26), per Nexqual as of November 18, 2026 at 20:53 UTC.

Consensus RatingBuy
Analyst Count5
Mean TargetUSD 22
High TargetUSD 26
Low TargetUSD 18
Buy / Hold / Sell5 / 0 / 0

Earnings (CARL)

Next Earnings Date2026-11-10
EPS EstimateUSD -0.39
Revenue Estimate$19.16M

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.11 vs est -0.39 ▲ beat
2026-06-30USD -0.39 vs est -0.4 ▲ beat
2026-03-31USD -0.26 vs est -0.4 ▲ beat
2025-12-31USD -0.29 vs est -0.43 ▲ beat

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financials & Fundamentals (CARL)

Total Revenue$71.78M
Revenue Growth (latest quarter, YoY)+64.90%
Gross Margin+76.96%
Operating Margin-58.98%
Profit Margin-55.82%
ROE-43.95%
Debt / Equity0.29
Current Ratio5.79
Total Cash$80.21M
Total Debt$21.79M
Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K)-$34.92M (-48.6% of revenue)

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financial Health Score (CARL)

Nexqual rates Carlsmed, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.

GrowthStrong — Revenue +60% (last 4 quarters to Sep 2026 vs the 4 before, SEC)
ProfitabilitySolid — Gross margin 77%, operating -59% (last 4 quarters to Sep 2026, SEC)
Balance SheetStrong — $60M cash and investments vs $15M debt (Sep 2026, SEC), net cash
Cash FlowWeak — FCF negative: -$35M (last 4 quarters to Sep 2026, SEC), burning cash
EfficiencyCritical — ROE -53%, ROA -34.8% (last 4 quarters, SEC)

Ownership (CARL)

Insider Ownership+43.27%
Institutional Ownership+44.03%
Shares Outstanding27.40M
Float15.75M
Short % of Float+12.04%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Leadership (CARL)

Carlsmed, Inc. is led by Michael John Cordonnier, Co-Founder, Chairman, CEO & President, per Nexqual as of November 18, 2026 at 20:53 UTC.

Co-Founder, Chairman, CEO & PresidentMichael John Cordonnier
Co-Founder, Chief Intellectual Property Officer & DirectorNiall Patrick Casey
Chief Financial OfficerRichard J. Heppenstall
Chief Operating OfficerJeff Bertolini
Chief Technology OfficerShariq Hussain

Major Backers & Investors (CARL)

Notable institutional backers of Carlsmed, Inc. include Jupiter Topco LLC, JANUS INVESTMENT FUND-Janus Henderson Venture Fund, Parkman Healthcare Partners LLC, according to Nexqual as of November 18, 2026 at 20:53 UTC.

Active Investors

InvestorStake
Jupiter Topco LLC4.57%
JANUS INVESTMENT FUND-Janus Henderson Venture Fund2.23%
Parkman Healthcare Partners LLC2.18%
Pier Capital, LLC1.89%
Millennium Management1.08%
Palumbo Wealth Management Llc0.97%
Russell Investments Group, Ltd.0.94%

Index Funds (Passive)

FundStake
BlackRock2.12%
Vanguard Group1.03%
Geode Capital0.86%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

From Carlsmed, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
HTFLHeartflow, Inc.USD 46.01▼ 2.25%
EVHEvolent Health, IncUSD 3.95▼ 14.5%
NRCNRC HealthUSD 26.06▲ 0.68%
CTEVClaritev CorporationUSD 21.95▼ 4.35%
SOPHSOPHiA GENETICS SAUSD 7.47▲ 0.27%
PHRPhreesia, Inc.USD 12.31▼ 1.99%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt